We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

113 hedge funds and large institutions have $399M invested in CytomX Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 34

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

2% more funds holding

Funds holding: 111 → 113 (+2)

1.73% less ownership

Funds ownership: 83.92% → 82.19% (-1.7%)

29% less capital invested

Capital invested by funds: $561M → $399M (-$162M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $5K

Holders
113
Holders Change
+2
Holders Change %
+1.8%
% of All Funds
2.45%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
16
Increased
45
Reduced
34
Closed
14
Calls
–
Puts
$5K
Net Calls
-$5K
Net Calls Change
-$172K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$17.7M
2
GPP
Great Point Partners
Connecticut
+$14.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$14.1M
4
Victory Capital Management
Victory Capital Management
Texas
+$10.9M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$9.17M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$56M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$14.8M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.4M
4
DM
Deerfield Management
New York
-$9.4M
5
Fidelity International
Fidelity International
Bermuda
-$6.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
CPC
26
Congress Park Capital
New York
$2.27M +$1.3M +88,195 +72%
AG
27
Artal Group
Luxembourg
$2.15M +$739K +50,000 +33%
Goldman Sachs
28
Goldman Sachs
New York
$2.12M -$4.45M -300,717 -60%
BBA
29
Baker Bros. Advisors
New York
$2.09M +$2.87M +194,377 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2M +$14.1K +954 +0.5%
SFM
31
Sphera Funds Management
Israel
$1.97M -$1.33M -90,000 -33%
AllianceBernstein
32
AllianceBernstein
Tennessee
$1.81M +$1.03M +69,917 +71%
GIM
33
Granahan Investment Management
Massachusetts
$1.68M -$106K -7,156 -4%
TCIM
34
TIAA CREF Investment Management
New York
$1.64M -$183K -12,359 -7%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$1.51M +$1.41M +95,460 +212%
Squarepoint
36
Squarepoint
New York
$1.47M +$843K +57,004 +71%
USAA
37
United Services Automobile Association
Texas
$1.46M +$74.2K +5,022 +4%
JP Morgan Chase
38
JP Morgan Chase
New York
$1.45M -$127K -8,611 -6%
Bank of America
39
Bank of America
North Carolina
$1.37M +$1.06M +71,869 +129%
MCM
40
Moore Capital Management
New York
$1.34M – – –
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
$1.29M +$1.78M +120,274 New
Morgan Stanley
42
Morgan Stanley
New York
$1.23M +$449K +30,385 +36%
Fidelity International
43
Fidelity International
Bermuda
$1.21M -$6.71M -454,036 -80%
VIA
44
Vident Investment Advisory
Georgia
$1.12M -$34.8K -2,355 -2%
ACM
45
Aquilo Capital Management
California
$1.09M -$6.25M -422,996 -81%
EAM
46
Exane Asset Management
France
$1.07M +$739K +50,000 +100%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$1.04M +$451K +30,484 +46%
Two Sigma Investments
48
Two Sigma Investments
New York
$1.02M -$1.36M -91,787 -49%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$973K +$1.34M +90,495 New
Millennium Management
50
Millennium Management
New York
$967K -$1.01M -68,501 -43%
1
2
3 4 5

CTMX Hedge Fund Activity: Q1 2019 in Review

113 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2019, worth a combined $399M — down 29% from $561M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new CTMX positions and 14 closed out — a net gain of 2 holders — while 45 added to existing stakes and 34 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $17.7M. The largest seller was Fidelity Investments, cutting an estimated $56M.

  • 113 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2019, up from 111 in Q4 2018.
  • Funds reported $399M of CytomX Therapeutics stock for Q1 2019, down 29% quarter-over-quarter.
  • 16 funds opened new CytomX Therapeutics positions in Q1 2019 and 14 closed out, a net change of +2 holders.
  • The largest CytomX Therapeutics buyer in Q1 2019 was BVF Inc, an estimated $17.7M added.
  • The largest CytomX Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $56M sold.

Based on aggregated 13F filings for Q1 2019.